Welcome to our dedicated page for Bwx Technologies news (Ticker: BWXT), a resource for investors and traders seeking the latest updates and insights on Bwx Technologies stock.
BWX Technologies, Inc. reports developments tied to its nuclear manufacturing, engineering, and services businesses for government and commercial customers. Recurring updates include U.S. Naval Nuclear Propulsion Program contracts, long-lead reactor and component manufacturing, commercial nuclear equipment, and work connected to nuclear fuel and uranium-enrichment capabilities.
Company news also covers operating and financial results for its Government Operations and Commercial Operations segments, capital actions, governance changes, and regulatory engagement involving nuclear licensing. BWXT’s recurring business themes span global security, clean energy, nuclear medicine, space exploration, and environmental restoration.
BWX Technologies (NYSE: BWXT) has appointed Suzanne Maddux as senior vice president, operations, a newly created role reporting to President and CEO Rex Geveden. The position is intended to support BWXT’s growth in nuclear national security and commercial nuclear power markets.
Maddux will lead Environmental Health and Safety, Security, Operational Excellence and Supply Chain, and oversee manufacturing operations, engineering and quality. A key mandate is to strengthen connections between BWXT’s Government Operations and Commercial Operations to share learning and replicate proven practices. She joins from Mercury Systems, previously spending 18 years at RTX in senior operations-related roles.
BWX Technologies (NYSE: BWXT) reported second quarter 2026 revenue of $901.6 million, up 18% year over year, with Government Operations at $601.3 million (+2%) and Commercial Operations at $302.5 million (+72%). GAAP net income was $89.1 million and adjusted EBITDA reached $155.5 million, both higher than 2025.
Diluted GAAP EPS was $0.97 and non-GAAP EPS $1.07, up 14% and 5%, respectively. Free cash flow was $115.0 million, down 9% on higher capital expenditures of $41.4 million. BWXT announced the sale of its medical business and closed the acquisition of Precision Components Group on July 1, 2026 to expand U.S. commercial nuclear manufacturing. The company raised its 2026 guidance to revenue of about $3.8 billion, adjusted EBITDA of $662–$672 million, non-GAAP EPS of $4.70–$4.80, and free cash flow of $345–$360 million.
BWX Technologies (NYSE: BWXT) has signed a definitive agreement to sell its medical business to healthcare-focused investor Nordic Capital in a transaction valued at up to $800 million. The deal includes BWXT Medical and Kinectrics’ stable medical isotopes business, with BWXT retaining a meaningful minority stake in the new company.
According to BWX Technologies, the sale is intended to free capital and management resources to accelerate growth in its core nuclear national security and commercial nuclear power markets. BWXT will continue to provide specialized isotope and radiochemical expertise to the divested business. Management noted that since acquiring the medical unit in 2018, BWXT has roughly tripled its revenue, improved profitability and broadened its product portfolio with therapeutic isotopes. The transaction remains subject to customary regulatory approvals and is expected to close by the end of 2026.
BWX Technologies (NYSE: BWXT) has completed its acquisition of Precision Components Group (PCG), including Precision Custom Components and DC Fabricators.
The deal adds over 500,000 square feet of U.S. heavy nuclear manufacturing capacity, a workforce of 450+ employees, and strengthens BWXT’s commercial and U.S. Navy nuclear components capabilities.
BWX Technologies (NYSE: BWXT) will release its second quarter 2026 financial results on Monday, August 3, 2026, after market close, followed by a conference call at 5:00 p.m. EDT.
Investors can join via webcast at investors.bwxt.com or by phone using the provided U.S. and international dial-in numbers.
ATI (NYSE: ATI) signed a new five-year strategic material supply agreement with BWX Technologies (NYSE: BWXT), extending their support for the U.S. Naval Nuclear Propulsion Program through fiscal 2030.
ATI will provide specialty materials for nuclear applications, leveraging decades of defense and materials science expertise.
BWX Technologies (NYSE: BWXT) reported that its TRISO nuclear fuel powered Antares Nuclear’s reactor to the first successful criticality under Executive Order 14301 reforming DOE reactor testing.
BWXT also processed HALEU feedstock from NNSA scrap and continues ongoing TRISO manufacturing for Antares, highlighting scalable U.S. advanced reactor fuel capabilities.
BWX Technologies (NYSE: BWXT) announced U.S. Naval Nuclear Propulsion Program contracts totaling more than $1.4 billion dated May 7, 2026. The awards include a $1.285 billion contract for fiscal 2026 long-lead material procurement (first of five annual task order awards through 2030) and a $165 million contract for long-lead reactor components and manufacturing for Ford-class carriers, with work at Barberton, OH and Mount Vernon, IN.
BWXT also noted recent shipment of four Ford-class steam generators to the USS Doris Miller (CVN 81).
BWX Technologies (NYSE: BWXT) reported 1Q26 results: revenue $860.2M, GAAP net income $91.2M, GAAP diluted EPS $0.99, and adjusted EBITDA $148.0M. The company announced the acquisition of Precision Components Group to establish U.S. commercial nuclear component capacity and raised 2026 guidance to adjusted EBITDA $650M–$665M, non-GAAP EPS $4.60–$4.75, and free cash flow $315M–$330M.
1Q26 revenue rose 26% YoY, driven by Commercial Operations (+121%), and operating cash flow improved to $92.6M with free cash flow of $50.1M.
BWX Technologies (NYSE: BWXT) agreed to acquire Precision Components Group, including Precision Custom Components and DC Fabricators, expanding U.S. commercial nuclear manufacturing capacity.
The deal adds approximately $125 million in 2025 revenue, > 500,000 sq ft of heavy-manufacturing space and ~400 employees; closing expected in H2 2026, subject to approvals.